159 related articles for article (PubMed ID: 20334671)
1. Phenotypic effects of the circadian gene Cryptochrome 2 on cancer-related pathways.
Hoffman AE; Zheng T; Ba Y; Stevens RG; Yi CH; Leaderer D; Zhu Y
BMC Cancer; 2010 Mar; 10():110. PubMed ID: 20334671
[TBL] [Abstract][Full Text] [Related]
2. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.
Hoffman AE; Zheng T; Stevens RG; Ba Y; Zhang Y; Leaderer D; Yi C; Holford TR; Zhu Y
Cancer Res; 2009 Apr; 69(8):3605-13. PubMed ID: 19318546
[TBL] [Abstract][Full Text] [Related]
3. The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.
Mao Y; Fu A; Hoffman AE; Jacobs DI; Jin M; Chen K; Zhu Y
Tumour Biol; 2015 May; 36(5):3533-9. PubMed ID: 25740058
[TBL] [Abstract][Full Text] [Related]
4. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.
Hoffman AE; Zheng T; Yi CH; Stevens RG; Ba Y; Zhang Y; Leaderer D; Holford T; Hansen J; Zhu Y
Cancer Prev Res (Phila); 2010 Apr; 3(4):539-48. PubMed ID: 20233903
[TBL] [Abstract][Full Text] [Related]
5. Cryptochrome 2 (CRY2) Suppresses Proliferation and Migration and Regulates Clock Gene Network in Osteosarcoma Cells.
Yu Y; Li Y; Zhou L; Yang G; Wang M; Hong Y
Med Sci Monit; 2018 Jun; 24():3856-3862. PubMed ID: 29879092
[TBL] [Abstract][Full Text] [Related]
6. Deregulated expression of cryptochrome genes in human colorectal cancer.
Mazzoccoli G; Colangelo T; Panza A; Rubino R; De Cata A; Tiberio C; Valvano MR; Pazienza V; Merla G; Augello B; Trombetta D; Storlazzi CT; Macchia G; Gentile A; Tavano F; Vinciguerra M; Bisceglia G; Rosato V; Colantuoni V; Sabatino L; Piepoli A
Mol Cancer; 2016 Jan; 15():6. PubMed ID: 26768731
[TBL] [Abstract][Full Text] [Related]
7. The circadian gene Cryptochrome 2 influences stress-induced brain activity and depressive-like behavior in mice.
Sokolowska E; Viitanen R; Misiewicz Z; Mennesson M; Saarnio S; Kulesskaya N; Kängsep S; Liljenbäck H; Marjamäki P; Autio A; Callan SA; Nuutila P; Roivainen A; Partonen T; Hovatta I
Genes Brain Behav; 2021 Apr; 20(4):e12708. PubMed ID: 33070440
[TBL] [Abstract][Full Text] [Related]
8. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response.
Hoffman AE; Zheng T; Ba Y; Zhu Y
Mol Cancer Res; 2008 Sep; 6(9):1461-8. PubMed ID: 18819933
[TBL] [Abstract][Full Text] [Related]
9. DNA damage shifts circadian clock time via Hausp-dependent Cry1 stabilization.
Papp SJ; Huber AL; Jordan SD; Kriebs A; Nguyen M; Moresco JJ; Yates JR; Lamia KA
Elife; 2015 Mar; 4():. PubMed ID: 25756610
[TBL] [Abstract][Full Text] [Related]
10. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer.
Gauger MA; Sancar A
Cancer Res; 2005 Aug; 65(15):6828-34. PubMed ID: 16061665
[TBL] [Abstract][Full Text] [Related]
11. Suppression of circadian clock protein cryptochrome 2 promotes osteoarthritis.
Bekki H; Duffy T; Okubo N; Olmer M; Alvarez-Garcia O; Lamia K; Kay S; Lotz M
Osteoarthritis Cartilage; 2020 Jul; 28(7):966-976. PubMed ID: 32339698
[TBL] [Abstract][Full Text] [Related]
12. Mammalian cryptochromes impinge on cell cycle progression in a circadian clock-independent manner.
Destici E; Oklejewicz M; Saito S; van der Horst GT
Cell Cycle; 2011 Nov; 10(21):3788-97. PubMed ID: 22033214
[TBL] [Abstract][Full Text] [Related]
13. DNA damage-specific control of cell death by cryptochrome in p53-mutant ras-transformed cells.
Lee JH; Gaddameedhi S; Ozturk N; Ye R; Sancar A
Cancer Res; 2013 Jan; 73(2):785-91. PubMed ID: 23149912
[TBL] [Abstract][Full Text] [Related]
14. USP7 and TDP-43: Pleiotropic Regulation of Cryptochrome Protein Stability Paces the Oscillation of the Mammalian Circadian Clock.
Hirano A; Nakagawa T; Yoshitane H; Oyama M; Kozuka-Hata H; Lanjakornsiripan D; Fukada Y
PLoS One; 2016; 11(4):e0154263. PubMed ID: 27123980
[TBL] [Abstract][Full Text] [Related]
15. PRKCDBP (CAVIN3) and CRY2 associate with major depressive disorder.
Kovanen L; Donner K; Kaunisto M; Partonen T
J Affect Disord; 2017 Jan; 207():136-140. PubMed ID: 27721187
[TBL] [Abstract][Full Text] [Related]
16. DYRK1A and glycogen synthase kinase 3beta, a dual-kinase mechanism directing proteasomal degradation of CRY2 for circadian timekeeping.
Kurabayashi N; Hirota T; Sakai M; Sanada K; Fukada Y
Mol Cell Biol; 2010 Apr; 30(7):1757-68. PubMed ID: 20123978
[TBL] [Abstract][Full Text] [Related]
17. Cry2 Is Critical for Circadian Regulation of Myogenic Differentiation by Bclaf1-Mediated mRNA Stabilization of Cyclin D1 and Tmem176b.
Lowe M; Lage J; Paatela E; Munson D; Hostager R; Yuan C; Katoku-Kikyo N; Ruiz-Estevez M; Asakura Y; Staats J; Qahar M; Lohman M; Asakura A; Kikyo N
Cell Rep; 2018 Feb; 22(8):2118-2132. PubMed ID: 29466738
[TBL] [Abstract][Full Text] [Related]
18. Circadian disruption does not alter tumorigenesis in a mouse model of lymphoma.
Mello RM; Pariollaud M; Lamia KA
F1000Res; 2023; 12():49. PubMed ID: 37811199
[No Abstract] [Full Text] [Related]
19.
Chan AB; Parico GCG; Fribourgh JL; Ibrahim LH; Bollong MJ; Partch CL; Lamia KA
Proc Natl Acad Sci U S A; 2021 Jul; 118(27):. PubMed ID: 34183418
[TBL] [Abstract][Full Text] [Related]
20. Cryptochrome 2 acetylation attenuates its antiproliferative effect in breast cancer.
Xia K; Li S; Yang Y; Shi X; Zhao B; Lv L; Xin Z; Kang J; Ren P; Wu H
Cell Death Dis; 2023 Apr; 14(4):250. PubMed ID: 37024472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
